An interventional study of Arthrosamid in Knee Osteoarthristis, sponsored by Medisch Centrum Latem. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Medisch Centrum Latem · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 33rd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2024, is one of 25 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 45th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Next Biomedical Co., Ltd. · Sites in Belgium, Netherlands
Ages 50+
Medisch Centrum Latem · Sites in Belgium
Ages 18–85
Ziekenhuis Oost-Limburg · Sites in Belgium, Netherlands
Ages 18+
Sint-Trudo Hospital · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 86 across the 38 interventional studies, 190 across the 8 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 46 have an industry lead sponsor. The 10 most frequent:
Medisch Centrum Latem is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Medisch Centrum Latem has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Knee with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387473Vrije Universiteit BrusselAdded Value of Cognitive Behavioural Therapy for Insomnia in Persons With Knee Osteoarthritis | 2026-12 |
| NCT07465601Medisch Centrum LatemDaily Activity and Clinical Outcome Measurement of Arthrosamid® Administration in Symptomatic Knee Osteoarthritis. | 2027-01-31 |
| NCT06930677Next Biomedical Co., Ltd.Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200 | 2027-02 |
| NCT06891807Medisch Centrum LatemComparison of Image Based Robotic Total Knee Arthroplasty vs Imageless Augmented Reality Assisted Total Knee Arthroplasty | 2027-10-01 |
| NCT02766231Limacorporate S.p.aPhysica CR and Physica PS Clinical Trial | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, monocentric, interventional post-market study evaluating the effects of a single intra-articular injection of Arthrosamid in patients with symptomatic knee osteoarthritis. Arthrosamid is a polyacrylamide hydrogel consisting of 97.5% sterile water and 2.5% cross-linked polyacrylamide that integrates into the synovial tissue and is used for the symptomatic treatment of knee osteoarthritis.
The study will include 30 eligible patients receiving a single Arthrosamid injection and will be followed for up to 12 months. The primary objective is to evaluate the performance of Arthrosamid in terms of daily activities and clinical outcomes in patients with symptomatic knee osteoarthritis. The primary endpoint assesses the percentage change from baseline in daily activity levels at 6 months after injection, measured using an activity tracker combined with a digital rehabilitation tool. Additional assessments include patient-reported outcome measures and clinical follow-up visits conducted as part of standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Advanced osteoarthritis, involving one or multiple of the following phenotypes: tricompartmental osteoarthritis, isolated or severe patella-femoral osteoarthritis, and/or a Kellgren and Lawrence grade II or III classification:
Exclusion Criteria:
Meeting one of the following as stated in the instructions for use (IFU) of Arthrosamid®:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with symptomatic knee osteoarthritis receiving a single intra-articular injection of Arthrosamid and followed for clinical outcomes and activity levels for up to 12 months.
Device: Arthrosamid
Single intra-articular injection of Arthrosamid, a polyacrylamide hydrogel consisting of 97.5% sterile water and 2.5% cross-linked polyacrylamide, administered for the symptomatic treatment of knee osteoarthritis.
Percentage Change From Baseline in Daily Activity Levels
Percentage change from baseline in daily activity levels at 6 months after a single intra-articular Arthrosamid injection, measured using an activity tracker coupled with a digital rehabilitation tool.
Time frame: 6 months follow-up
Percentage Change From Baseline in Daily Activity Levels
Percentage change from baseline in daily activity levels at 12 months after a single intra-articular Arthrosamid injection, measured using an activity tracker coupled with a digital rehabilitation tool.
Time frame: 12 months follow-up
Change From Baseline in Patient-Reported Outcome Measures
Absolute and percentage change from baseline in patient-reported outcome measures (PROMs), including KOOS (total and subscales), Oxford Knee Score, Forgotten Joint Score (FJS), EQ-5D, UCLA Activity Score, and the moveUP index score, in patients with symptomatic knee osteoarthritis treated with Arthrosamid.
Time frame: 7 to 14 days before injection, Day 0 (baseline), 2 weeks, 6 weeks, 3 months, 6 months, and 12 months follow-up
Rescue Medication Consumption
Consumption of concomitant or rescue medication in patients with symptomatic knee osteoarthritis following a single intra-articular Arthrosamid injection, assessed at multiple follow-up time points.
Time frame: 2 weeks, 6 weeks, 3 months, 6 months, and 12 months follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 30 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 30 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medisch Centrum Latem